NL300336I1 - Vaccin tegen de bof dat een jeryl-lynn virusstam bevat - Google Patents

Vaccin tegen de bof dat een jeryl-lynn virusstam bevat

Info

Publication number
NL300336I1
NL300336I1 NL300336C NL300336C NL300336I1 NL 300336 I1 NL300336 I1 NL 300336I1 NL 300336 C NL300336 C NL 300336C NL 300336 C NL300336 C NL 300336C NL 300336 I1 NL300336 I1 NL 300336I1
Authority
NL
Netherlands
Prior art keywords
jeryl
virus strain
vaccine containing
mumps vaccine
lynn
Prior art date
Application number
NL300336C
Other languages
English (en)
Other versions
NL300336I2 (nl
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939323820A external-priority patent/GB9323820D0/en
Priority claimed from GB9406480A external-priority patent/GB9406480D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NL300336I1 publication Critical patent/NL300336I1/nl
Publication of NL300336I2 publication Critical patent/NL300336I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0015Combination vaccines based on measles-mumps-rubella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165Mumps or measles virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18711Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761Methods of inactivation or attenuation
    • C12N2760/18762Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36211Rubivirus, e.g. rubella virus
    • C12N2770/36234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NL300336C 1993-11-19 2008-02-12 Vaccin tegen de bof dat een jeryl-lynn virusstam bevat NL300336I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939323820A GB9323820D0 (en) 1993-11-19 1993-11-19 Vaccine
GB9406480A GB9406480D0 (en) 1994-03-31 1994-03-31 Vaccine
PCT/EP1994/003801 WO1995014083A1 (en) 1993-11-19 1994-11-15 Vaccine against mumps containing a jeryl-lynn virus strain

Publications (2)

Publication Number Publication Date
NL300336I1 true NL300336I1 (nl) 2008-04-01
NL300336I2 NL300336I2 (nl) 2009-01-05

Family

ID=26303889

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300336C NL300336I2 (nl) 1993-11-19 2008-02-12 Vaccin tegen de bof dat een jeryl-lynn virusstam bevat

Country Status (20)

Country Link
US (4) US6024962A (nl)
EP (2) EP0729509B1 (nl)
JP (1) JPH09504954A (nl)
KR (1) KR100362051B1 (nl)
CN (2) CN1150819A (nl)
AT (1) ATE266090T1 (nl)
AU (1) AU687922B2 (nl)
CA (1) CA2176929C (nl)
CY (2) CY2540B1 (nl)
DE (3) DE69433760T2 (nl)
DK (1) DK0729509T3 (nl)
ES (1) ES2219658T3 (nl)
HK (1) HK1012421A1 (nl)
LU (1) LU91458I2 (nl)
NL (1) NL300336I2 (nl)
NZ (1) NZ276102A (nl)
PT (1) PT729509E (nl)
SG (1) SG52780A1 (nl)
SI (1) SI0729509T1 (nl)
WO (1) WO1995014083A1 (nl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150819A (zh) 1993-11-19 1997-05-28 史密斯克莱·比奇曼生物公司 含有jeryl-lynn病毒株的抗流行性腮腺炎疫苗
MXPA02001177A (es) * 1999-08-02 2002-07-02 Wyeth Corp Recuperacion del virus de las paperas del acido desoxirribonucleico recombinante.
RS59774B1 (sr) * 2015-03-27 2020-02-28 Cadila Healthcare Ltd Vakcina zasnovana na rekombinantnom jeryl lynn 2 virusu zauški
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
CN114457046A (zh) * 2022-02-16 2022-05-10 科兴(大连)疫苗技术有限公司 一种稀释法传代纯化腮腺炎病毒的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555149A (en) 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
CN1150819A (zh) 1993-11-19 1997-05-28 史密斯克莱·比奇曼生物公司 含有jeryl-lynn病毒株的抗流行性腮腺炎疫苗

Also Published As

Publication number Publication date
PT729509E (pt) 2004-09-30
DE122007000003I1 (de) 2007-05-24
DE69433760D1 (de) 2004-06-09
DK0729509T3 (da) 2004-08-16
NZ276102A (en) 1998-04-27
US6899884B2 (en) 2005-05-31
EP1484391A1 (en) 2004-12-08
US20020018784A1 (en) 2002-02-14
LU91458I2 (fr) 2008-08-25
EP0729509B1 (en) 2004-05-06
CY2008005I1 (el) 2012-01-25
SI0729509T1 (en) 2004-08-31
US20040120969A1 (en) 2004-06-24
KR100362051B1 (ko) 2003-04-11
CY2540B1 (en) 2006-06-28
US20030095984A1 (en) 2003-05-22
CA2176929C (en) 2002-04-30
DE122007000003I2 (de) 2011-01-13
NL300336I2 (nl) 2009-01-05
AU687922B2 (en) 1998-03-05
US6024962A (en) 2000-02-15
KR960705919A (ko) 1996-11-08
CN101948816A (zh) 2011-01-19
US6656476B2 (en) 2003-12-02
WO1995014083A1 (en) 1995-05-26
JPH09504954A (ja) 1997-05-20
DE69433760T2 (de) 2005-05-12
SG52780A1 (en) 1998-09-28
HK1012421A1 (en) 1999-07-30
EP0729509A1 (en) 1996-09-04
CA2176929A1 (en) 1995-05-26
ATE266090T1 (de) 2004-05-15
CN1150819A (zh) 1997-05-28
AU8144194A (en) 1995-06-06
CY2008005I2 (el) 2018-01-10
ES2219658T3 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
HU9904549A (en) Vaccines
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
AU1471797A (en) Hybrid protein between CS from plasmodium and HBsAG
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
DK0639640T3 (da) Fjerkrævaccine indeholdende smitsomt bronchitis-virus serotype 4/91
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
NL300336I1 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
FR2693655B1 (fr) Vaccin antirabique avirulent.
DK0744027T3 (da) Anvendelse af fremgangsmåder til identifikation af hydrofile signaloligopeptider
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
EP0636030A4 (en) VACCINE AGAINST THE -I BACTERIAL OXIDE (PASTEURELLIA HAEMOLYTICA).
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.